HC Wainwright issues updated earnings estimates for Dianthus and Delcath

Equities researchers at HC Wainwright have issued updated earnings estimates and ratings for Dianthus Therapeutics and Delcath Systems.

For Dianthus Therapeutics, analyst S. Ramakanth raised the Q3 2026 earnings per share (EPS) estimate to ($1.00) from a previous forecast of ($1.43). HC Wainwright maintains a "Buy" rating on the stock with a $158.00 price objective. The company recently reported revenue of $0.76 million for the quarter, exceeding analyst estimates of $0.30 million, though it reported an EPS of ($0.90), missing the consensus estimate of ($0.85).

Regarding Delcath Systems, HC Wainwright analyst S. Ramakanth expects the company to post earnings of ($0.05) per share for Q1 2027. The firm holds a "Buy" rating for the company with a $32.00 target price. Delcath Systems recently reported quarterly revenue of $29.13 million, which exceeded the consensus estimate of $26.25 million, and reported an EPS of $0.07, surpassing the consensus estimate of ($0.09).